Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CCR1 | P32246 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5562551 | 0.92 | HPGD (0.42) | MAPTCCR1TSHRALDH1A1CYP3A4 | |
| SCHEMBL5561323 | 0.88 | CCR1 (0.46) | MAPTCCR1TSHRALDH1A1CYP3A4 | |
| SCHEMBL5556406 | 0.87 | ALDH1A1 (0.36) | MAPTALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5561526 | 0.81 | CASP1 (0.43) | MAPTCCR1TSHRSMN1; SMN2HTT | |
| SCHEMBL5562635 | 0.81 | MAPT (0.43) | MAPTCCR1TSHRALDH1A1CYP3A4 | |
| SCHEMBL5556392 | 0.80 | TP53 (0.56) | MAPTCCR1TSHRALDH1A1CYP3A4 | |
| SCHEMBL5562089 | 0.79 | MAPT (0.44) | MAPTCCR1TSHRALDH1A1CYP3A4 | |
| SCHEMBL5561543 | 0.79 | ACKR3 (0.43) | MAPTCCR1 | |
| SCHEMBL5555754 | 0.79 | EPHX1 (0.42) | MAPTCCR1TSHRALDH1A1CYP3A4 | |
| SCHEMBL5561808 | 0.79 | TSHR (0.42) | MAPTCCR1TSHRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631296-B1 | 2,3,4,5-TETRAHYDROBENZO¬F|¬1,4|OXAZEPINE-5-CARBOXYLIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-7060698-B2 | Benzoxazepinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20040235819-A1 | 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. | HOFFMANN-LA ROCHE INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235819-A1 | 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. | BACE1, BACE2, PSEN1 | MAPT 318/4885CCR1 4708/4885TSHR 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.